Key Highlights

● Remlifanserin 60 mg narrowly missed the primary endpoint, with a p-value of 0.0603.

● The key secondary measure showed a nominal p-value of 0.0077 at 60 mg.

● ACADIA will continue two Phase 3 studies, amended to remove the 30 mg arm.

● Second-quarter revenue was $308 million, and cash totalled $956 million.

On 24 September 2026 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), which trades on Nasdaq as ACAD, reported topline results from the Phase 2 part of RADIANT, a global, randomised, double-blind, placebo-controlled study of remlifanserin in psychosis associated with Alzheimer's disease. The Phase 2 part compared 60 mg and 30 mg once-daily doses with placebo within a seamless Phase 2/3 programme.

The primary endpoint was the change from baseline at week 6 on the SAPS-H+D scale. The 60 mg dose improved by 12.6 points against 10.4 for placebo, an effect size of 0.26, with a p-value of 0.0603, so it did not reach conventional statistical significance. On the key secondary measure, CGI-S-ADP, the 60 mg dose improved by 1.3 points against 0.9, an effect size of 0.37 and a nominal p-value of 0.0077. The 30 mg dose showed minimal improvement over placebo.

The company reported adverse events, serious adverse events and discontinuations similar to placebo, no signal of QT prolongation, and no deaths in the remlifanserin arms. The release did not state enrolment or arm sizes.

Why the programme continues

The company framed the data as supporting Phase 3, and it will continue its two ongoing Phase 3 studies in Alzheimer's psychosis, amending them to remove the 30 mg arm. Detailed results will be given as an oral presentation at the CTAD conference in Boston from 16 to 19 November 2026.

The wording is the company's interpretation. Removing the weaker dose concentrates the programme on the dose that showed clearer separation from placebo. The August release also recorded that remlifanserin had received FDA Fast Track designation and that Phase 3 enrolment had begun. A missed primary endpoint with a nominal secondary result is not proof of benefit, and the Phase 3 studies must still succeed independently. A separate Phase 2 study in Lewy body dementia psychosis is also ongoing, the release says.

The commercial base funding the work

The latest financial report covers the quarter ended 30 June 2026 and was released on 4 August 2026. Total revenue was $308 million, up 16% on a GAAP basis. Net product sales of NUPLAZID were $183 million, up 9%, whilst DAYBUE sales rose 30% to $125 million from $96 million, which management linked to uptake of DAYBUE STIX. Net income was $32 million, or $0.18 per diluted share, compared with $27 million, or $0.16, a year earlier.

Cash, cash equivalents and investment securities totalled $956 million at 30 June 2026, compared with $820 million at the end of 2025. That balance gives the company room to fund late-stage development without relying on the Phase 2 outcome alone.

Management guidance

For 2026 the company raised its GAAP total revenue guidance to $1.24 billion to $1.30 billion from $1.22 billion to $1.28 billion. DAYBUE guidance rose to $480 million to $510 million, NUPLAZID guidance stayed at $760 million to $790 million, and research and development spending guidance was lowered to $355 million to $380 million from $385 million to $410 million. Selling, general and administrative expense is expected at $660 million to $700 million. These are management expectations, not analyst forecasts.

The August release also noted that the European medicines regulator's committee had adopted a positive opinion on DAYBUE for Rett syndrome, with a European Commission decision pending at that date.

CTAD in November and Unscheduled Phase 3 Readouts Mark What Comes Next

The next disclosed milestones are the CTAD presentation in November and the progress of the amended Phase 3 studies, for which no readout dates have been disclosed.